Conference Proceedings

Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Y-L Wu, TSK Mok, J-Y Han, M-J Ahn, A Delmonte, SS Ramalingam, S-W Kim, FA Shepherd, J Laskin, Y He, H Akamatsu, WSME Theelen, W-C Su, T John, M Sebastian, H Mann, M Miranda, G Laus, Y Rukazenkov, V Papadimitrakopoulou

Annals of Oncology | Elsevier BV | Published : 2019

Citation metrics